Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 341 across all filing types
Latest filing 2022-06-29 Board/Management Inform…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Inify Laboratories announces the appointment of Chief Medical Officer (CMO)
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of a new senior executive, Dr. Claes Lind, to the role of Chief Medical Officer (CMO). This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2022-06-29 English
Inify Laboratories ansetter Chief Medical Officer fra Karolinska
Board/Management Information Classification · 100% confidence The document is a press release dated June 29, 2022, announcing the hiring of a new Chief Medical Officer (CMO), Dr. Claes Lindh. The content focuses entirely on management changes, detailing the new executive's background and the strategic importance of the appointment. This directly matches the definition for Board/Management Information (MANG). The document is short and appears to be a direct announcement, not a formal regulatory filing like a 10-K or IR, nor is it a general regulatory filing (RNS) as a more specific category exists.
2022-06-29 Norwegian
Inify Laboratories announces the appointment of Chief Medical Officer (CMO)
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of a new senior executive, Dr. Claes Lind, to the role of Chief Medical Officer (CMO). This content directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management.
2022-06-29 English
Inify Laboratories - now listed on Euronext Growth in Oslo under the INIFY ticker
Regulatory Filings Classification · 90% confidence The document is explicitly titled an "INFORMATION DOCUMENT" prepared by INIFY Laboratories AB solely for the purpose of "Admission to trading of shares on Euronext Growth". It details the structure, risks, organization, financial information, and share capital related to this listing event. This type of document, prepared to comply with specific exchange admission rules (Euronext Growth Admission Rules) and containing comprehensive details about the company for potential investors in connection with a listing, is best classified as a type of prospectus or offering/listing document. Since there is no specific code for an 'Admission Document' or 'Prospectus' (though it explicitly states it is *not* a prospectus under EU 2017/1129), we must choose the closest fit among the provided options. It is a comprehensive document providing detailed financial and operational information required for a public market entry. It is much more detailed than a simple Earnings Release (ER) or a Fund Factsheet (FS). Given its comprehensive nature covering financials, risks, and governance for a public offering/listing context, it shares characteristics with an Annual Report (10-K) or an Interim Report (IR) in terms of depth, but its purpose is listing admission. However, since it is a document detailing the company's structure and financial position for a public market event, and it contains audited interim accounts (Appendix 2), it functions as a primary disclosure document. If the company were already listed and filing periodically, it might be an IR or 10-K. Since it is for admission, and it contains detailed financial sections, it is closest in scope to a comprehensive report. Given the options, and recognizing that this document serves as the primary disclosure for a new listing, it is most analogous to a comprehensive report required for public status. If we consider the context of a new listing disclosure, it is a foundational document. Since it contains audited interim accounts and extensive financial review sections (Section 6, 7), it is more substantial than a simple announcement. In the absence of a specific 'Listing Document' code, and noting its comprehensive nature, it is often grouped with major regulatory filings. However, the document structure strongly suggests a formal disclosure document required for listing, which often substitutes for or precedes a full 10-K/IR if the company is newly public. Given the options, and the fact that it is a detailed, structured report, it is not a simple announcement (RPA/RNS). It is a foundational disclosure. Since it contains audited interim accounts (Appendix 2), it leans towards a comprehensive report. If the company is newly public, this document serves as the initial comprehensive filing. We will classify it as a comprehensive report, leaning towards the Annual Report (10-K) structure if it were yearly, or Interim Report (IR) if it were quarterly. Since it covers the company's structure and financial position leading up to the listing, and contains audited financials for a period, it fits the scope of a comprehensive report. Given the document's focus on the admission process and its structure, it is a specific type of offering/listing document. Since 'CAP' (Capital/Financing Update) is too narrow, and '10-K' implies a standard annual filing, 'IR' (Interim Report) is also specific to a shorter period. Because this document is a formal, comprehensive disclosure required for listing, and it contains audited financials, it is a major disclosure. We select 'IR' as the closest fit for a comprehensive financial disclosure document that isn't the annual report, acknowledging the context is a listing document.
2022-06-20 English
Inify Laboratories - now listed on Euronext Growth in Oslo under the INIFY ticker
Regulatory Filings Classification · 85% confidence The document is titled "INFORMATION DOCUMENT" prepared by INIFY Laboratories AB in connection with the "Admission to trading of shares on Euronext Growth". It explicitly states that it is an Information Document prepared to comply with the Euronext Growth Admission Rules and that it does *not* constitute a prospectus. This type of document, detailing company information, risk factors, management, and financial overview specifically for an initial listing or admission to trading on an MTF (like Euronext Growth), is a specialized disclosure document. While it contains elements of an Annual Report (10-K) or Interim Report (IR) due to the financial sections, its primary purpose and regulatory context (Admission Rules) align best with a comprehensive disclosure document required for listing. Since there is no specific code for an 'Admission Document' or 'Prospectus Equivalent', and given its comprehensive nature (over 167k characters, detailed sections on financials, management, risks, and share capital), it is a major regulatory disclosure. However, it is not a standard 10-K (Annual Report) or IR (Interim Report). It is a document providing detailed information for investors prior to trading. Given the options, and recognizing this is a comprehensive disclosure document required for listing, it is closest in scope to a major filing, but none fit perfectly. Since it is a detailed document providing extensive information required for a specific corporate action (listing), and not just an announcement of a report (RPA) or a general regulatory filing (RNS), I must choose the best fit among the provided definitions. It is not an AGM-R, ER, CT, or DVA. It contains governance info (CGR) and financial info (IR/10-K elements), but its context is listing. In many contexts, a listing document of this nature is often classified as a specialized prospectus equivalent or a detailed investor presentation/report. Given the structure and depth, it is more than just an Investor Presentation (IP). Since it is a formal, required document detailing the company's structure, risks, and financials for public admission, and lacks the specific headers of 10-K or IR, it functions as a comprehensive disclosure. If we must choose from the list, and recognizing it is a formal, required disclosure document detailing the company's structure and financials for listing, it is most analogous to a detailed report or presentation. Given the options, and the fact that it is a formal document detailing the company's structure, risks, and financials for public admission, it is a significant disclosure. Since it is not a standard periodic report (10-K, IR), and not just a presentation (IP), and not an announcement (RPA), I will classify it as a comprehensive disclosure document. Since there is no specific 'Listing Document' code, and it is a formal, required document, I will lean towards the most comprehensive report type that covers financials and operations, or the general regulatory fallback. Given the depth, it is more than just an IP. I will classify it as a Regulatory Filing (RNS) as it is a specific regulatory disclosure document required by Euronext Growth Admission Rules, which doesn't fit the periodic financial reports (10-K, IR) or specific announcements (DIV, DIRS).
2022-06-20 English
Inify Laboratories - now listed on Euronext Growth in Oslo under the INIFY ticker
Capital/Financing Update Classification · 95% confidence The document announces that Inify Laboratories has been admitted to trading on Euronext Growth Oslo and mentions securing NOK 150 million in funding through an equity issue. It also announces an online presentation hosted by the CEO on the same day. This content relates to corporate financing, listing events, and investor communication, but it is not a formal regulatory report (like 10-K or IR) or a standard earnings release (ER). Since it discusses fundraising/capital structure changes ('equity issue towards supportive long-term shareholders') and is a general corporate announcement, the most fitting category is Capital/Financing Update (CAP). It is too specific for a general Regulatory Filing (RNS) and does not fit the definitions of the other specific reports.
2022-06-20 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.